Michelle Rashford

Chief Tech/Sci/R&D Officer at RACE ONCOLOGY LIMITED

Health Technology

Profile

Michelle Rashford is currently the Chief Medical Officer at Race Oncology Ltd.
Prior to this, she was the Vice President-Medical Science at Kyowa Kirin, Inc. from 2020 to 2022 and the Senior Vice President-Clinical Science at Hangzhou Adlai Nortye Biopharma Co. Ltd.
from 2018 to 2020.

Michelle Rashford active positions

Companies	Position	Start
RACE ONCOLOGY LIMITED	Chief Tech/Sci/R&D Officer	01/07/2023

All active positions of Michelle Rashford

Former positions of Michelle Rashford

Companies	Position	End
Kyowa Kirin, Inc.	Chief Tech/Sci/R&D Officer	01/10/2022
Hangzhou Adlai Nortye Biopharma Co. Ltd. Hangzhou Adlai Nortye Biopharma Co. Ltd. BiotechnologyHealth Technology Part of Adlai Nortye Ltd., Hangzhou Adlai Nortye Biopharma Co. Ltd. is a clinical-stage biopharmaceutical company based in Hangzhou, China. Adlai Nortye is developing differentiated, innovative immuno-oncology medicines with a focus on discovering and developing important new treatments for cancer. The Chinese company's mission is to improve patient lives by identifying and developing differentiated innovative medicines that help people live better and longer. The company was founded in 2004 by Yang Lu, Dong Hui Yang, and Yang Lu has been the CEO since then.	Chief Tech/Sci/R&D Officer	01/06/2020

See the detail of Michelle Rashford's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michelle Rashford's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
RACE ONCOLOGY LIMITED	Health Technology

Private companies	2
Hangzhou Adlai Nortye Biopharma Co. Ltd. Hangzhou Adlai Nortye Biopharma Co. Ltd. BiotechnologyHealth Technology Part of Adlai Nortye Ltd., Hangzhou Adlai Nortye Biopharma Co. Ltd. is a clinical-stage biopharmaceutical company based in Hangzhou, China. Adlai Nortye is developing differentiated, innovative immuno-oncology medicines with a focus on discovering and developing important new treatments for cancer. The Chinese company's mission is to improve patient lives by identifying and developing differentiated innovative medicines that help people live better and longer. The company was founded in 2004 by Yang Lu, Dong Hui Yang, and Yang Lu has been the CEO since then.	Health Technology
Kyowa Kirin, Inc.